NCT00923026
Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER+, PR+
Other Mutations: 
Breast Cancer Tissue: Neuroendocrine tumor (NET)
Recruitment Status: Enrolling by invitation

Drug Category: Other

Key Eligibility Criteria:

Gender: All
Age: 18 Years and older (Adult, Older Adult)
Location of Metastases: 
Additional Notes: Patient must have been enrolled in a National Cancer Institute Surgery Branch (NCI-SB) treatment protocol
Exclusions: 
https://ClinicalTrials.gov/show/NCT00923026